enfuvirtide

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1000 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.57 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.07 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.36 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4 hours	Lombardo F, Berellini G, Obach RS

Date	Agency	Company	Orphan
March 13, 2003	FDA	ROCHE
May 27, 2023	EMA	ROCHE REGISTRATION GMBH

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Schizophrenia	916.28	265.43	192	3547	14722	90609986
Hypomania	773.53	265.43	153	3586	8744	90615964
Jaundice cholestatic	731.28	265.43	149	3590	9894	90614814
Cholelithiasis	676.10	265.43	192	3547	52314	90572394
Psychotic disorder	563.07	265.43	149	3590	31081	90593627
Blood bilirubin increased	514.29	265.43	149	3590	43321	90581387
Hepatotoxicity	506.46	265.43	149	3590	45693	90579015
Asthma-chronic obstructive pulmonary disease overlap syndrome	417.60	265.43	83	3656	4816	90619892
Total lung capacity increased	415.56	265.43	83	3656	4938	90619770
Sarcoidosis	353.20	265.43	83	3656	10590	90614118
Nasal polyps	351.62	265.43	83	3656	10797	90613911
Rhinitis allergic	315.87	265.43	83	3656	16702	90608006
Cardiac murmur	309.24	265.43	83	3656	18111	90606597
Bronchiectasis	292.40	265.43	83	3656	22247	90602461

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Depression	1273.44	173.48	445	3435	110918	42506537
Drug interaction	930.32	173.48	456	3424	266543	42350912
Psychiatric decompensation	682.70	173.48	139	3741	4083	42613372
Mitochondrial toxicity	653.92	173.48	124	3756	2491	42614964
Depression suicidal	645.46	173.48	127	3753	3118	42614337
Tearfulness	635.88	173.48	127	3753	3373	42614082
Lipodystrophy acquired	613.63	173.48	123	3757	3327	42614128
Depressive symptom	570.72	173.48	118	3762	3735	42613720
Psychomotor skills impaired	535.37	173.48	118	3762	5086	42612369
Eyelid ptosis	532.99	173.48	123	3757	6538	42610917
Loss of personal independence in daily activities	494.90	173.48	181	3699	49635	42567820
Paranoia	455.88	173.48	126	3754	13900	42603555
Diplopia	392.80	173.48	122	3758	20194	42597261
Psychotic disorder	380.42	173.48	130	3750	29078	42588377
Progressive external ophthalmoplegia	359.20	173.48	68	3812	1343	42616112
Suicidal ideation	306.85	173.48	127	3753	48034	42569421
Anxiety	234.36	173.48	141	3739	118419	42499036

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psychotic disorder	958.88	202.67	278	6998	50659	110531364
Depression	928.16	202.67	438	6838	316897	110265126
Schizophrenia	771.65	202.67	196	7080	21630	110560393
Drug interaction	761.46	202.67	446	6830	499737	110082286
Hypomania	690.72	202.67	155	7121	10055	110571968
Psychiatric decompensation	677.43	202.67	138	7138	5627	110576396
Mitochondrial toxicity	660.08	202.67	123	7153	3122	110578901
Lipodystrophy acquired	649.60	202.67	128	7148	4396	110577627
Depression suicidal	629.38	202.67	126	7150	4698	110577325
Jaundice cholestatic	615.12	202.67	151	7125	14457	110567566
Tearfulness	575.72	202.67	126	7150	7269	110574754
Cholelithiasis	565.24	202.67	196	7080	63226	110518797
Psychomotor skills impaired	531.33	202.67	117	7159	6941	110575082
Depressive symptom	510.85	202.67	117	7159	8297	110573726
Eyelid ptosis	482.02	202.67	122	7154	13205	110568818
Paranoia	432.73	202.67	125	7151	22249	110559774
Hepatotoxicity	396.61	202.67	151	7125	63249	110518774
Total lung capacity increased	386.08	202.67	85	7191	5027	110576996
Progressive external ophthalmoplegia	380.54	202.67	68	7208	1352	110580671
Blood bilirubin increased	370.11	202.67	151	7125	75821	110506202
Asthma-chronic obstructive pulmonary disease overlap syndrome	367.80	202.67	85	7191	6259	110575764
Diplopia	340.33	202.67	121	7155	41773	110540250
Loss of personal independence in daily activities	337.04	202.67	174	7102	149846	110432177
Sarcoidosis	310.03	202.67	85	7191	12494	110569529
Nasal polyps	305.97	202.67	85	7191	13115	110568908
Rhinitis allergic	280.28	202.67	85	7191	17837	110564186
Suicidal ideation	261.05	202.67	126	7150	93811	110488212
Cardiac murmur	257.68	202.67	86	7190	24542	110557481
Bronchiectasis	221.05	202.67	85	7191	36408	110545615

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

enfuvirtide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	J05AX07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D023581	HIV Fusion Inhibitors
FDA MoA	N0000175615	Fusion Protein Inhibitors
FDA EPC	N0000175616	Human Immunodeficiency Virus 1 Fusion Inhibitor
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:59886	HIV fusion inhibitor
CHEBI has role	CHEBI:64946	anti-HIV agent

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Pneumonia	contraindication	233604007	DOID:552
Breastfeeding (mother)	contraindication	413712001
Smokes tobacco daily	contraindication	449868002

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.09	acidic
pKa2	3.55	acidic
pKa3	3.77	acidic
pKa4	3.97	acidic
pKa5	4.16	acidic
pKa6	4.38	acidic
pKa7	4.66	acidic
pKa8	9.65	acidic
pKa9	11.84	acidic
pKa10	12.17	acidic
pKa11	12.25	acidic
pKa12	12.34	acidic
pKa13	12.44	acidic
pKa14	12.6	acidic
pKa15	12.67	acidic
pKa16	12.74	acidic
pKa17	12.82	acidic
pKa18	12.92	acidic
pKa19	12.93	acidic
pKa20	13.14	acidic
pKa21	13.18	acidic
pKa22	13.22	acidic
pKa23	13.23	acidic
pKa24	13.3	acidic
pKa25	13.43	acidic
pKa26	13.44	acidic
pKa27	13.49	acidic
pKa28	13.53	acidic
pKa29	13.57	acidic
pKa30	13.59	acidic
pKa31	13.65	acidic
pKa32	13.78	acidic
pKa33	13.78	acidic
pKa34	13.8	acidic
pKa35	13.88	acidic
pKa36	13.93	acidic
pKa37	11.11	Basic
pKa38	10.51	Basic
pKa39	6.69	Basic

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Transmembrane glycoprotein gp41	Membrane other	O40239_9PLVG	INHIBITOR			CHEMBL	CHEMBL
Envelope glycoprotein	Viral envelope protein	Q53I07_9HIV1				WOMBAT-PK
GP41	Viral envelope protein	Q76270_9HIV1		EC50	8	CHEMBL

ID	Source
4021375	VUID
N0000171600	NUI
D02499	KEGG_DRUG
4021375	VANDF
C0537439	UMLSCUI
CHEBI:608828	CHEBI
CHEMBL525076	ChEMBL_ID
D000077560	MESH_DESCRIPTOR_UI
DB00109	DRUGBANK_ID
8063	INN_ID
19OWO1T3ZE	UNII
16130199	PUBCHEM_CID
139896	RXNORM
17175	MMSL
46376	MMSL
d04853	MMSL
009919	NDDF
398902008	SNOMEDCT_US
409127007	SNOMEDCT_US